Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is conducting a Phase 2 study titled A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer. The study aims to assess the safety and efficacy of various combinations of telisotuzumab adizutecan with other drugs in treating metastatic colorectal cancer (mCRC), a prevalent cancer type worldwide.
The study tests telisotuzumab adizutecan, an investigational drug, in combination with approved treatments like oxaliplatin, fluorouracil, leucovorin, bevacizumab, and panitumumab. These combinations are intended to evaluate adverse events and changes in disease activity in mCRC patients.
This interventional study is randomized with a parallel assignment model and no masking, focusing primarily on treatment. It involves dose escalation and dose optimization stages to determine the most effective and tolerable doses.
The study began on April 24, 2025, with an estimated duration of six years. The primary completion and estimated completion dates are yet to be announced. The latest update was submitted on June 25, 2025.
This study could significantly impact AbbVie’s stock performance and investor sentiment, given the potential for new treatment options in the competitive oncology market. Success in this study might position AbbVie favorably against competitors in the mCRC treatment landscape.
The study is ongoing, with further details available on the ClinicalTrials portal.